Real-world study supports tocilizumab as first-line biologic in DMARD-IR patients with RASeptember 17, 2023Rheumatoid Arthritis
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RASeptember 17, 2023Rheumatoid Arthritis
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RASeptember 17, 2023Rheumatoid Arthritis
Tapering TNFi raises disease flare likelihood in patients with RA even in those in remissionSeptember 17, 2023Rheumatoid Arthritis
Weight gain and increased BP concerns should not deter low-dose glucocorticoid use in RASeptember 17, 2023Rheumatoid Arthritis
Rheumatology NewsYour workplace is toxic: Can you make it better?September 13, 2023Business of Medicine
Rheumatology News12 steps to closing your practice without problemsSeptember 13, 2023Business of Medicine
Rheumatology NewsBenralizumab hits target for eosinophilic granulomatosis with polyangiitisSeptember 13, 2023Lupus & Connective Tissue DiseasesVasculitis
Rheumatology NewsDisenfranchised grief: What it looks like, where it goesSeptember 13, 2023Mixed Topics
Rheumatology NewsEarly glucocorticoid bridging in RA supported by meta-analysis, but concerns remainSeptember 13, 2023Rheumatoid Arthritis
Rheumatology NewsHydroxychloroquine blood level ‘sweet spot’ may maximize efficacy in lupusSeptember 12, 2023Lupus & Connective Tissue Diseases
